USP7 · Western blot design guide

USP7 Western Blot Planning Guide

Plan an USP7 Western blot around the catalog-observed 128.3 kDa band, image-backed A01239-2 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for USP7 (USP7): expected band 128.3 kDa, antibody A01239-2, and guide-derived SDS-PAGE protocol steps
USP7 Western blot protocol sheet — expected band 128.3 kDa, antibody A01239-2, controls and PMC citations. Open the full USP7 WB guide →

USP7 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 128.3 kDa
Observed band Not reported — verify product WB image
Gel 8-10%
Positive control ⓘ Cerebellum
Negative control ⓘ Smooth muscle
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 128.3 kDa
ⓘ Localization Nucleus / Cytoplasm
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated USP7 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAdrenal gland
Gel %8-10%
Load20-30 µg total protein per lane
TransferWet/tank, extended transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA01239-2 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected USP7 Western Blot Band Size?

Use the product-observed 128.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
128.3 kDaMatches the authoritative product WB observation.
128.3 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected USP7 appearancePlan around 128.3 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band128.3 kDa; use this as the primary experimental expectation.
Calculated mass128.3 kDa from UniProt Q93009; retain as context.
Gel selection8-10%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A01239-2.
Why is my band missing or off?
SituationLikely causeNext action
128.3 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for USP7 Western blot

🧪Use Cerebellum as the first positive-control candidate and Smooth muscle as the HPA Not detected negative candidate.
Positive control: Cerebellum (Medium)
Negative control: Smooth muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for USP7

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Cerebellum Reported tissue cells Medium Protein (HPA) HPA →
Adrenal gland Reported tissue cells Medium Protein (HPA) HPA →
Caudate Reported tissue cells Medium Protein (HPA) HPA →
Appendix Reported tissue cells Medium Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Smooth muscle Reported tissue cells Not detected Protein (HPA) HPA →
Soft tissue Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced USP7 Western Blot Tips

Deeper troubleshooting and optimisation questions for USP7, answered from its protein features.

Which band should guide the blot?
Use 128.3 kDa, the observation attached to the authoritative A01239-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 128.3 kDa expectation.
Which positive control should I start with?
Start with Cerebellum, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Smooth muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for USP7 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01239-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

USP7 Western Blot Reagents

Human/Mouse/Rat-reactive USP7 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for USP7 using A01239-2; observed band 128.3 kDa
Anti-HAUSP/USP7 Antibody Picoband®
Cat # A01239-2
Real WB data Western blot validation image for USP7 using M01239-1; observed band 128.3 kDa
Anti-HAUSP/USP7 Antibody Picoband® (monoclonal, 5E2)
Cat # M01239-1

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q93009
  2. Human Protein Atlas — USP7
  3. A01239-2 product record
  4. PMC12825427 — Potential Anti-Cancer Drug 6RK73 Suppresses Ovarian Cancer Growth by Inactivating the AKT1/Sp1 Induced c-Myc Signaling Pathway (Journal of Cancer, 2026)
  5. PMC9136619 — p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade (Cancer research, 2022)
  6. PMC9732911 — USP7 substrates identified by proteomics analysis reveal the specificity of USP7 (Genes & development, 2022)